狄诺塞麦的作用与功效

Theoretically, almost all types of cancer can spread (metastasize) to the bones. It is reported that 65%-75% of patients with metastatic breast cancer will develop bone metastases; 90% of patients with metastatic castration-resistant prostate cancer will develop bone metastases; 30%-40% of patients with advanced lung cancer will develop bone metastases. On June 13, 2013, Denosumab was approved to treat adults and adolescents with giant cell tumor of bone (GCTB), a rare and usually noncancerous tumor.

In addition to giant cell tumors of bone, denosumab (denosumab) is also miraculous in preventing SRE in solid tumors. The new indication application (sNDA) for denosumab (denosumab) for the prevention of bone-related events in patients with multiple myeloma and solid tumor bone metastases was officially accepted in April 2020 and is currently under technical review and approval by the Center for Drug Evaluation. Denosumab (denosumab) has been approved by the US FDA as early as 2010 for the treatment of skeletal-related events (SRE) in patients with solid tumor bone metastases, which undoubtedly brings more survival opportunities to patients.

Denosumab (denosumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody with high specificity and affinity for RANKL. RANK receptor signaling promotes osteolysis and tumor growth. Denosumab (denosumab) inhibits tumor growth and reduces bone destruction by binding to RANKL and preventing it from activating RANK on the surface of osteoclasts, osteoclast precursors and osteoclast-like giant cells.

Patients should note that denosumab (denosumab) can only be administered by subcutaneous injection, not intravenous infusion, intramuscular infusion or intradermal injection. Giant cell tumor of bone: 120 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. Administer calcium and vitamin D appropriately to prevent hypocalcemia.

(denosumab) has broad prospects and profound potential in delaying and preventing bone metastases, and will bring more innovative treatment options to patients with bone metastases.

Recommended related hot articles: /newsDetail/77915.html